Drug interactions
Bosentan + Polatuzumab vedotin
Severity: Minor
Bosentan and Polatuzumab vedotin: minor interaction.
Last updated
For healthcare professionals — reference only. This page is a brief summary, not medical advice and not a substitute for official labeling or clinical judgement. Always verify before prescribing or dispensing.
Summary
The cytotoxic payload of polatuzumab vedotin, MMAE, is metabolized by CYP3A4. Bosentan is only a moderate inducer, so any fall in MMAE exposure is expected to be small, though efficacy could be reduced.
What this interaction means in plain words
Bosentan and Polatuzumab vedotin have a small, usually unimportant interaction. Most people can take both; the pharmacist may still mention it so that any unexpected effect is recognised.
Bosentan belongs to Miscellaneous; Polatuzumab vedotin belongs to Oncology.
Why it happens
Bosentan induces CYP3A4, which may increase the clearance of unconjugated MMAE.
What to do
No dose adjustment is needed. Monitor the response to treatment.
What to ask your pharmacist
- Is there anything I should notice while taking both?
- Do I need to tell my doctor at the next visit?
Pro+ members
Unlock the full page
Create an account and start a Pro+ trial to unlock the full management advice for Bosentan and Polatuzumab vedotin, the additional notes, the evidence detail and the whole-prescription interaction checker.
- Full clinical management advice
- Additional notes
- Evidence detail
- Interaction checker for a whole prescription
Try Pro+ free for 7 days on the web. No card needed.
Other interactions of Bosentan
- Bosentan + Cyclosporin Contraindicated
- Bosentan + Glibenclamide Contraindicated
- Bosentan + Glyburide-metformin Contraindicated
- Bosentan + Lonafarnib Contraindicated
- Bosentan + Sparsentan Contraindicated
- Artemether / lumefantrine + Bosentan Major
Other interactions of Polatuzumab vedotin
Frequently asked questions
Can I take Bosentan with Polatuzumab vedotin?
MediHelp rates the interaction as minor. Bosentan and Polatuzumab vedotin have a small, usually unimportant interaction. Most people can take both; the pharmacist may still mention it so that any unexpected effect is recognised. The cytotoxic payload of polatuzumab vedotin, MMAE, is metabolized by CYP3A4. Bosentan is only a moderate inducer, so any fall in MMAE exposure is expected to be small, though efficacy could be reduced.
How serious is the interaction between Bosentan and Polatuzumab vedotin?
MediHelp rates it minor, on a four-level scale (minor, moderate, major, contraindicated) based on published labels and references. What to do, in brief: No dose adjustment is needed. Monitor the response to treatment.
What other medicines interact with Bosentan?
MediHelp also lists interactions of Bosentan with, for example, Cyclosporin, Glibenclamide, Glyburide-metformin. The full list is on the Bosentan page.
Full monographs, dosing and an interaction checker in the MediHelp app
Open the complete reference, check multi-drug interactions and use dosing tools in the MediHelp app.
